Source: Annual Congress 2011 - Acute respiratory failure
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
C. Marcu, R. Bals, A. Groeschel, C. Lensch, J. Woerner, S. Faendrich (Homburg, Germany). Inhalation of activated recombinant factor VII to treat pulmonary hemorrhage in a patient with cystic fibrosis. Eur Respir J 2011; 38: Suppl. 55, 2041

Member's Comments

No comment yet.

Related content which might interest you: The protease activated receptor (PAR)-2/tissue factor/coagulation factor VIIa axis in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Pulmonary expression of alternatively spliced tissue factor as a potential prognostic marker in idiopathic pulmonary fibrosis Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 PP309 – Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis Source: ERS Lung Science Conference 2021 Year: 2021 Recombinant thrombomodulin improves survival in acute exacerbation of idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients Source: Eur Respir J 2007; 29: 240-250 Year: 2007 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012 Coagulation and anticoagulation in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 392-399 Year: 2015 Inhalation therapy in cystic fibrosis Source: School Course 2013 - Cystic Fibrosis Year: 2013 Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 266s Year: 2005 Massive hemoptysis in cystic fibrosis adult patients Source: Annual Congress 2008 - Cystic fibrosis: factors affecting lung health Year: 2008 LATE-BREAKING ABSTRACT: Coagulation factor IX deficiency does not afford protection from pulmonary fibrosis in the experimental murine bleomycin model Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012 VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Predictive factors for severe pulmonary exacerbations in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 715s Year: 2006 Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis Source: ERJ Open Res, 4 (1) 00111-2017; 10.1183/23120541.00111-2017 Year: 2018 Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1393-1402 Year: 2015 Aetiology of non cystic fibrosis bronchiectasis and its correlation with the site of pulmonary damage Source: Eur Respir J 2003; 22: Suppl. 45, 504s Year: 2003 Pulmonary hypertension in cystic fibrosis patients Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008 Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis Source: Eur Respir J, 49 (5) 1700178; 10.1183/13993003.00178-2017 Year: 2017